- Home
- LTH vs IONS Comparison
LTH vs IONS Comparison
Compare LTH & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTH
- IONS
- Stock Information
- Founded
- LTH 1992
- IONS 1989
- Country
- LTH United States
- IONS United States
- Employees
- LTH N/A
- IONS N/A
- Industry
- LTH Hotels/Resorts
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- LTH Consumer Discretionary
- IONS Health Care
- Exchange
- LTH Nasdaq
- IONS Nasdaq
- Market Cap
- LTH 6.3B
- IONS 6.8B
- IPO Year
- LTH 2021
- IONS 1991
- Fundamental
- Price
- LTH $29.22
- IONS $42.25
- Analyst Decision
- LTH Buy
- IONS Buy
- Analyst Count
- LTH 13
- IONS 15
- Target Price
- LTH $34.42
- IONS $57.13
- AVG Volume (30 Days)
- LTH 2.8M
- IONS 1.8M
- Earning Date
- LTH 08-05-2025
- IONS 07-30-2025
- Dividend Yield
- LTH N/A
- IONS N/A
- EPS Growth
- LTH 174.52
- IONS N/A
- EPS
- LTH 0.96
- IONS N/A
- Revenue
- LTH $2,730,319,000.00
- IONS $717,253,000.00
- Revenue This Year
- LTH $14.65
- IONS $9.08
- Revenue Next Year
- LTH $11.45
- IONS $14.72
- P/E Ratio
- LTH $30.40
- IONS N/A
- Revenue Growth
- LTH 18.58
- IONS N/A
- 52 Week Low
- LTH $20.22
- IONS $23.95
- 52 Week High
- LTH $34.99
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- LTH 48.11
- IONS 60.76
- Support Level
- LTH $28.38
- IONS $41.25
- Resistance Level
- LTH $30.80
- IONS $42.81
- Average True Range (ATR)
- LTH 0.75
- IONS 1.18
- MACD
- LTH -0.10
- IONS -0.27
- Stochastic Oscillator
- LTH 34.89
- IONS 42.36
About LTH Life Time Group Holdings Inc.
Life Time Group Holdings Inc is a lifestyle and leisure brand offering health, fitness, and wellness experiences to a community. It is engaged in designing, building, and operating distinctive and large, multi-use sports and athletic, professional fitness, family recreation, and spa centers in a resort-like environment, principally in residential locations of metropolitan areas in the United States and Canada.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.